TADO
21.10.2021 10:02:09 CEST | Business Wire | Press release
With heating and cooling of homes accounting for 21% of the EU’s energy consumption, European housing stock urgently needs decarbonising in order to lower emissions 55% by 2030 and achieve net-zero1 according to a new report from Gemserv and tado°.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021005179/en/
To realise these goals and reduce CO2 emissions, approximately €600 billion has been reserved in the EU’s Green Deal funds2 . Decarbonisation is a huge challenge for governments across Europe, and any spending must be used as effectively and efficiently to not incur higher costs to the taxpayer.
A new report produced by research consultancy Gemserv looked at the four most common methods of decarbonising homes in Europe and found that compared to solar PV, heat pumps, and insulation, smart thermostats offered the most cost effective first step to decarbonisation based on the upfront cost and carbon saved.
On average a smart thermostat from tado° saves 22% of energy used in homes across Europe, based on data provided by over 1 million connected thermostats3 . If all homes in Europe were equipped with smart thermostats, the total carbon emissions across Europe could fall by 4.75%, a sizeable contribution to the 55% goal by 2030.
According to tado°, the cost for implementing smart thermostats in all European homes would be approximately €40 billion, or 6.67% of the total cost allocated for the European Green Deal. To achieve the same 4.75% reduction in emissions through other infrastructure would be much more costly; the next best alternative heat pumps require ten times the investment at €432 billion, €2.25 trillion for insulation, solar PV being €2.81 trillion, sizeable portion of the EU’s investment funds.
The report also highlights that in order for the EU to achieve its targets for CO2 emissions these measures must work in tandem. Heat pumps, insulation and solar PV are all recognised methods of decarbonising for the future, and will each play an important role in achieving the net-zero goal of 2050. Heat pumps, solar PV, smart thermostats and insulation can all play a large role in decarbonising a single home together.
“Intelligently controlled low carbon heating, renewable electricity generation, and insulation upgrades will all play a key role in household decarbonisation. However, this report demonstrates that smart thermostats offer consistent financial returns, whilst saving carbon – unique amongst the four technologies we have analysed” says Christopher Lewis, Economic Analyst at Gemserv.
Christian Deilmann, Co-Founder and CPO of tado° the leader in intelligent home climate management says “The European Green Deal needs to recognise these findings, and use their budget wisely to make a real difference on an international level. Smart thermostats clearly offer the most cost efficient use of taxpayer funds”
“If policymakers were to incentivise the uptake of smart thermostats as they have for other measures, homes would waste less energy and our net-zero target would be achieved much sooner and at lower cost,” Deilmann continued.
The report was peer reviewed by Dr. Tim Forman, Senior Research Associate, University Cambridge who says “Smart thermostats show compelling potential to reduce energy demand, thereby reducing energy-related carbon emissions, based on the study assumptions.”
With the low-barrier for entry, and ease of use, policymakers, governments and building regulators should recognise this study and bring about government incentives for smart thermostats in-line with the European Green Deal’s Renovation Wave and to better help foster smart thermostat’s up-take.
To read the report please visit http://www.tado.com/Energy-Efficiency . For more information on Smart Thermostats and their benefits visit www.tado.com .
About Gemserv
Gemserv is an expert provider of professional services in a world driven by data and technology. It is a purpose-driven company, working across multiple sectors, including energy, the public sector and health to tackle today's social and environmental challenges. The business provides consultancy and outsourcing capabilities to make markets work better, to help organisations harness the power of digital transformation and to ensure people's data is better protected and used ethically. www.gemserv.com
About Dr. Tim Forman
Dr. Tim Forman (BA MSc PhD) is a Senior Research Associate at the Cambridge Institute for Sustainability Leadership, University of Cambridge. Dr Forman’s research, teaching and professional background relates to the design, construction and renovation of buildings and to improving sustainability and resilience in the built environment under current and future climate conditions.
About tado°
tado° is the European leader in intelligent home climate management. As the only cross-manufacturer platform, tado° Smart Thermostats and services connect with any kind of heating or cooling system. Customers benefit from energy-saving technology such as Geofencing and Open Window Detection, as well as from remote heating diagnostics. Founded in Munich, 2011, and with 180 employees, tado° reshapes the way energy is consumed for more comfort, savings, and wellbeing at home. www.tado.com
1 Source: Decarbonisation of Heat: Why it Needs Innovation , 18 March 2020
2 Based on the planned One third of the 1.8 trillion euro investments from the NextGenerationEU Recovery Plan, not including the EU’s seven-year budget which will also finance the European Green Deal. Source: https://ec.europa.eu/info/strategy/priorities-2019-2024/european-green-deal_en
3 Average savings from over 1,000,000 connected thermostats, data provided by tado GmbH.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005179/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
